Output Explorer

Every prompt in the paper, and what each model wrote back.

Return exactly ten single-sentence facts as JSON. Quality was judged pairwise; here you see the raw outputs and whether the JSON parsed.

13 of 1,000 prompts

RXST · Q1 20262026-05-06 VEL · Q2 20252025-08-07 HPE · Q2 20262026-06-01 QS · Q4 20252026-02-11 MLYS · Q1 20262026-05-06 MSFT · Q1 20262025-10-29 VTGN · Q2 20262025-11-13 ASO · Q1 20262026-06-09 DLHC · Q3 20252025-08-07 OTIS · Q2 20252025-07-23 LIDR · Q4 20252026-03-16 LMND · Q3 20252025-11-05 WAL · Q3 20252025-10-22

Nearby prompts. All 1,000 Earnings calls prompts

PromptVTGN· Q2 2026 · call on2025-11-13· transcript 21,367 characters

Analyze the following earnings call transcript and extract the 10 most investor-relevant facts.

Each fact must:
- Be drawn only from the transcript (do not use any outside information).
- Be a single sentence capturing a specific, quantified insight relevant to investors.
- Avoid regurgitating the transcript verbatim; instead, synthesize and distill the information into investor-relevant facts.

Return only a JSON object with this exact structure (no markdown fences, no commentary):
{"facts": ["<fact 1>", "<fact 2>", ..., "<fact 10>"]}

The list must contain exactly 10 facts.

Transcript:
<transcript>
transcript redacted — the source calls are not publicly licensed
</transcript>

System prompt · identical for every setup

You are a financial analyst. You extract the most investor-relevant facts from earnings call transcripts to help investors anticipate the stock's reaction to the call.

Reference

No reference summary is published. Quality was judged pairwise by a separate model and is reported in aggregate on the main page.

Ours

10 facts · valid JSON

Vistagen completed the last patient visit for the pivotal Phase III PALISADE-3 trial evaluating intranasal fasedienol for social anxiety disorder.
The company expects to release top-line results from the PALISADE-3 study by the end of the current calendar year.
Enrollment for the PALISADE-3 trial reached the original target of 236 patients who completed the last patient visit.
Top-line results for the parallel Phase III PALISADE-4 trial are currently on track to be reported in the first half of 2016.
As of September 30, 2025, Vistagen held $77.2 million in cash, cash equivalents, and marketable securities.
Management estimates an NDA submission for fasedienol could occur around the middle of 2026 if pivotal trial data remains positive.
The company currently believes its lead asset fasedienol does not fall within the scope of the Commissioner's Priority Review Voucher program.
Observed usage patterns from long-term safety studies indicate fasedienol is primarily utilized during week hours rather than weekends.
Minimal effect sizes deemed clinically meaningful for PALISADE-3 are targeted to replicate the statistically and clinically significant outcomes achieved in the prior PALISADE-2 study.
The company maintains strategic flexibility regarding the commercialization model for fasedienol, considering both internal execution and potential strategic partnerships.

Aux 2015

Invalid JSONshown as written

{
"facts": [
"1. Vistagen Therapeutics, Inc. (VSTX) has built a strong momentum as we enter into what could be a potentially transformative period for Vistagen. Last week, we announced another major milestone in our PALISADE-3 program for fasedienol and social anxiety disorder. The last patient completed the randomized double-blind portion of our PALISADE-3 Phase III trial, evaluating our most advanced intranasal “pherines” product candidate, fasedienol for the acute treatment of social anxiety disorder. We are now preparing for the release of top line results from the PALISADE-3 study by the end of this calendar year. We extend our sincere gratitude to the patients who participated in the study as well as the dedicated and experienced clinical investigators, the clinical site staff and our contract research organization. Their enthusiasm, their focus on detail and the collaboration throughout the study were notable and greatly appreciated and will remain so during the ongoing open-label extension of the study.",
"2. Shawn Singh, President and CEO, will provide a brief business update, clinical update, and Josh Prince, Chief Operating Officer, will be available to provide additional feedback during the Q&A portion of our call. After our remarks, we will take questions from the sell-side analysts joining us today. I remind you, a replay of the webcast will be made available in the Events section of our Investor page on our website.",
"3. As of September 30, 2025, we had $77.2 million in cash, cash equivalents and marketable securities. We believe current cash covers all known aspects of our ongoing U.S. registration-directed PALISADE program for fasedienol for the acute treatment of SAD, including potential NDA submission if our PALISADE program is successful. Before I conclude the business update, I'd like to welcome Mr. Paul Edick to our Board of Directors. Paul joins us at a pivotal time for Vistagen, bringing decades of experience leading successful FDA approvals, commercial launches and strategic transactions. His leadership will be invaluable as we prepare for our next phase of growth.",
"4. Our mission remains clear and unwavering: to redefine what is possible in neuroscience, to restore emotional well-being and improve quality of life for millions worldwide. With a diverse and innovative pipeline, experienced team, several key milestones approaching, we believe we are entering one of the most exciting and potentially transformative periods in our company's history with deep confidence in our ability to deliver meaningful value for patients and for our stockholders. I want to thank you all for your continued interest, your support and your engagement with Vistagen. It makes a lot of difference, and we look forward to sharing our progress with you in the weeks and the months ahead."
]
}

PiT-FT 2015

Invalid JSONshown as written

<|transcript|> <|assistant|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript|> <|transcript

ChronoGPT 2015

Invalid JSONshown as written